Where Medicine
Meets Markets
Healthcare finance intelligence for the next generation of analysts, investors, and scientists.
Our Thinking
Insights at the Intersection of Life Sciences and Markets
What We Do
Healthcare Finance Intelligence
Research & Analysis
Deep dives, company analyses, educational primers, and open financial models from our global analyst team.
Expert Conversations
Conversations with leaders across biotech, healthcare finance, and the life sciences.
Fall 2026 Curriculum
Eleven weeks, from life sciences fundamentals to biotech valuation, M&A, and strategic finance.
Collaborations
Expert interviews, guest analysis, and partnerships with professionals, students, and organizations.
Conversations
Expert Interviews
Conversations with leaders across biotech, healthcare finance, and the life sciences. Watch interview highlights on our Instagram.
Our Team
A Global Team of Student Analysts
BioAsset is built on a simple belief: the best work happens when curious people are given real ownership.
About BioAsset
The most important developments in healthcare are driven by capital, science, and policy working together.
BioAsset exists to make that intersection legible to the next generation of analysts, investors, and physicians.
We publish rigorous, accessible research.
Deep dives, company analyses, and educational primers from analysts free to pursue the topics that excite them, whether that’s an FDA catalyst, a pipeline valuation, or a landmark deal reshaping the industry.
Read Our ResearchWe build open financial models.
Our Tectonic Therapeutic (TECX) long thesis comes with the full memo and the financial model to download.
We train student analysts to think across disciplines.
Our analysts come from diverse academic backgrounds spanning biochemistry, economics, public health, and beyond, united by a genuine curiosity about how science creates value.
Meet the TeamAnd we do it all in public.
Our Clients
Companies We Work With
Companies & Labs
Past Interviews
Our Thinking
Insights
Deep dives, company analyses, educational primers, and open financial models from our global analyst team.
Interviews & Media
Conversations
Conversations with leaders across biotech, healthcare finance, and the life sciences.
Expert Interviews
On Instagram
Video Interviews
Companies & Labs
Past Interviews
For Professionals
Expert Interviews
Share your perspective with our audience of students and industry professionals across biotech, pharma, and healthcare finance.
Our Analysts
Our Team
BioAsset is built on a simple belief: the best work happens when curious people are given real ownership.
Leadership
Analysts & Outreach
How We Work
Our analysts aren’t siloed into rigid roles or buried under busywork. Every member of the team contributes meaningfully to research, writing, and editorial review, and no one’s contribution matters less than anyone else’s.
We sit at the intersection of life sciences and finance, and our team reflects that. Our analysts come from diverse academic backgrounds spanning biochemistry, economics, public health, and beyond, united by a genuine curiosity about how science creates value. That cross-disciplinary perspective is what makes our content sharper than what you’d find at a typical student org.
We also believe great output starts with genuine interest. Analysts have the flexibility to pursue the topics that excite them, whether that’s an FDA catalyst, a pipeline valuation, or a landmark deal reshaping the industry. When people care about what they’re researching, the quality speaks for itself.
If you want to do serious, professional-level work in healthcare finance alongside people who are just as driven and curious as you are, BioAsset is the place.
Growing Team
Apply to Join
BioAsset is built by a global team of student analysts passionate about the intersection of healthcare and capital markets.
About BioAsset
Where Medicine Meets Markets
Healthcare finance intelligence for the next generation of analysts, investors, and scientists.
Our Mission
The most important developments in healthcare are driven by capital, science, and policy working together. BioAsset exists to make that intersection legible to the next generation of analysts, investors, and physicians.
We publish rigorous, accessible research. We build open financial models. We train student analysts to think across disciplines. And we do it all in public.
What We Do
Research & Analysis
Deep dives, company analyses, educational primers, and open financial models from our global analyst team.
Explore InsightsInterviews & Media
Conversations with leaders across biotech, healthcare finance, and the life sciences.
Explore ConversationsOur Team
BioAsset is built on a simple belief: the best work happens when curious people are given real ownership.
Meet the TeamFall 2026 Curriculum
Eleven weeks that take our analysts from life sciences fundamentals to biotech valuation, M&A, and strategic finance.
See the CurriculumClients & Partnerships
Life sciences companies work with BioAsset on strategic marketing, founder stories, and analyst-led projects. ReMinded is our first official partner.
See the PartnershipAdvisory Board
An advisory board of industry leaders, researchers, and founders is being formed to guide our research and programs.
Advisory BoardQuestions
Frequently Asked Questions
What is BioAsset?
BioAsset is a student-run research platform at the intersection of life sciences and capital markets. A global team of student analysts publishes deep dives, company analyses, educational primers, and open financial models, and interviews leaders across biotech, healthcare finance, and the life sciences. Its tagline is “Where Medicine Meets Markets.”
Who founded BioAsset?
BioAsset was founded by Dmitry Vysotskiy, its Founder & President, a student at NYU Stern. Alay Galvankar is Lead Analyst & Vice President and Joy Wu is Lead Analyst.
What does BioAsset publish?
BioAsset publishes research posts on biotech, pharma, and healthcare companies: company analyses, industry deep dives, FDA approval explainers, investment pitches, and financial models. This site has 47 posts by 10 analysts, including “The Quiet (and Growing) Giant of US Healthcare: Cardinal Health”, “Long Aktis Oncology (AKTS): Investment Pitch”, “The FDA has approved Takeda’s oveporexton, the first orexin agonist for narcolepsy”. Every post can also be read as an article.
Who has BioAsset interviewed?
BioAsset has interviewed Sofia Axelrod (Co-Founder & CEO, Circadian OS); Jay Schiff (Addinex Technologies); Andy Bolt (Deloitte Life Sciences); Dr. Ron Marks (Biostatistician); Annika Lundström (Co-Founder & CEO, ReMinded); Dr. Ayoub Glia (Scientist & Engineer, AMMLab, NYU Abu Dhabi); Dr. Paul Glimcher (Professor of Neuroscience & Economics, NYU); Dr. Michele Pagano (Chair, Department of Biochemistry & Molecular Pharmacology, NYU); Dr. Hao Su (Director, Biomechatronics & Intelligent Robotics Lab, NYU Tandon). Upcoming: Dr. Omar B. Lateef (President & CEO, RUSH University System for Health).
Who are BioAsset’s clients and partners?
ReMinded, a New York medtech building clinical-grade saliva testing, starting with cortisol, is BioAsset’s official partner and a client since Fall 2026. The work together covers strategic marketing and campaigns, with a consulting project or case study to follow.
What does the BioAsset Fall 2026 curriculum cover?
The Fall 2026 curriculum runs 11 weeks: (1) Introduction to BioAsset and Life Sciences + Careers + Resume Workshop; (2) How Money Flows Through the Healthcare Ecosystem; (3) Biotech & Pharma Fundamentals; (4) Clinical Trials & Clinical Data; (5) FDA, Regulation & Catalysts; (6) Commercialization & Market Access; (7) Healthcare History, Ethics & Current Problems; (8) Biotech Revenue Forecasting; (9) How to Analyze a Public Healthcare Company; (10) Biotech Valuation & Investment Thinking; (11) M&A, Licensing & Strategic Finance + Fun Activities. Throughout the term, analysts create weekly posts, and the program includes potential field trips to life sciences startups and guest speakers on Zoom.
How can I join BioAsset?
Students can apply through the team application on the Join page of bioasset.info. BioAsset looks for student analysts interested in the intersection of healthcare and capital markets.
How can I work with or contact BioAsset?
Professionals can take part in an expert interview, students and early-career writers can publish a guest analysis, and organizations can partner on content and events. Details are on the Collaborate page. Email bioasset@bioasset.info, or find BioAsset on LinkedIn, Instagram, TikTok, and YouTube.
Companies & Labs
Past Interviews
Contact
Get in Touch
Whether you want to read, write, model, or just learn, there’s a place for you.
Work With Us
Collaborate With BioAsset
We partner with professionals, students, and organizations operating at the intersection of life sciences and capital markets. If your work touches biotech, healthcare finance, or drug development, there’s likely a way we can work together.
Collaboration Tracks
How to Get Involved
Whether you’re an industry veteran, an aspiring analyst, or a student organization, we’ve built structured ways to collaborate.
For Professionals
Expert Interviews
Share your perspective with our audience of students and industry professionals across biotech, pharma, and healthcare finance.
Format: 30–45 min recorded conversation, published as editorial content across our channels.
Ideal for: Biotech investors, sell-side analysts, pharma executives, academic researchers, and clinician-scientists.
Express InterestFor Students & Early-Career
Guest Analysis
Publish a biopharma or healthcare finance deep dive with full author credit, reviewed by our editorial team.
Format: Written analysis piece — company breakdown, sector overview, or financial model walkthrough — edited and published under your name.
Ideal for: Students, graduate researchers, and early-career professionals building a public portfolio in healthcare finance.
Featured each month: One standout submission is selected as our Research Post of the Month, distributed across all BioAsset channels for maximum visibility.
Submit a PitchFor Organizations
Partnerships
We work with student groups, platforms, and organizations on cross-promotion, co-produced content, and joint events.
Format: Flexible — audience swaps, co-hosted panels, shared research projects, or event sponsorship.
Ideal for: University finance and biotech clubs, healthcare-focused media platforms, and life sciences organizations.
Start a ConversationGet in Touch
Have Something Else in Mind?
Reach out directly and we’ll find the right way to work together.
Companies & Labs
Past Interviews
Join the Team
Team Application
BioAsset is built by a global team of student analysts passionate about the intersection of healthcare and capital markets. If that sounds like you, we’d like to hear from you.
Team Application
Team Application Form
Tell us about your background, interests, availability, and the kind of work you want to do with BioAsset.
Community
Join the Conversation
Whether you want to read, write, model, or just learn, there’s a place for you.
Collaborate With UsOur Team
Serious Work, Real Ownership
If you want to do serious, professional-level work in healthcare finance alongside people who are just as driven and curious as you are, BioAsset is the place.
Meet the TeamFall 2026
Fall Curriculum
Eleven weeks that take our analysts from the foundations of life sciences and healthcare finance to valuation, dealmaking, and strategic finance.
Applied Throughout
Weekly Posts
Analysts create weekly posts in their chosen position.
Field Trips
Potential field trips to life sciences startup headquarters.
Guest Speakers
Talks with guest speakers, held on Zoom.
Join Us
Apply to Join
BioAsset is built by a global team of student analysts passionate about the intersection of healthcare and capital markets.
Clients
Our Clients
Life sciences companies work with BioAsset to reach the next generation of analysts, investors, and physicians, and to put a team of student analysts to work on real questions.
Current Clients
What We Do for Clients
How We Work Together
Strategic Marketing & Campaigns
Our team works closely with a client on marketing strategy and campaigns across our channels.
Founder Stories & Explainers
Founder conversations, office visits, and short explainers that make the science and the business behind a company clear.
Consulting Projects & Case Studies
A team of student analysts takes on a question the client chooses and presents its research.
Work With Us
Become a Client
Tell us what you are building and what you need. We’ll find the right way to work together.
Official Partner · Fall 2026
BioAsset Is Partnering With ReMinded
A New York medtech building clinical-grade saliva testing, starting with cortisol, now working with the student platform where science meets finance.
Official Partner
The Company
Clinical-Grade Saliva Testing, Starting With Cortisol
ReMinded is building the leading saliva-testing platform for hormones and metabolic markers, making it as easy for patients and clinicians to monitor biology as it is to check blood pressure.
with standard laboratory cortisol assays in real human saliva1
as the first commercial customers
from the U.S. Food and Drug Administration, and first revenue
Current clinical focus: long-term cortisol monitoring for endocrinology and precision mental-health clinics. Final clinical validation is underway at Hoag Hospital.
1. Agreement with standard laboratory cortisol assays in human saliva samples. Source: ReMinded company materials, November 2026.

The Founder
Annika Lundström
Co-Founder & CEO, ReMinded
Former Youth Olympian
Molecular bioscientist, University of Helsinki
Moved alone from Finland to the U.S. two years ago to build ReMinded in New York
Several million dollars raised, a top-tier scientific and engineering team assembled in the heart of NYC, saliva-based cortisol testing advanced through human-sample validation, and clinical partnerships established with leading U.S. healthcare institutions.
Source: ReMinded company materials, November 2026.
What’s Next
Where This Partnership Goes
Inside the Office
We’re heading into ReMinded’s NYC office to film the team and a full end-to-end demo of the device, from saliva strip to result.
The Story Behind the Science
Founder conversations and short explainers on what cortisol reveals, and where saliva testing goes next: other hormones and metabolic markers.
Students at the Table
The BioAsset team will work closely with ReMinded on strategic marketing and campaigns, with a consulting project or case study to follow.
On Instagram
Our Conversations With ReMinded
For Organizations
Partner With BioAsset
We work with student groups, platforms, and organizations on cross-promotion, co-produced content, and joint events.
Guidance
Advisory Board
BioAsset is forming an advisory board of industry leaders, researchers, and founders to guide our research, our programs, and our growth.
Members
The Board’s Role
Research Standards
Advisors will help keep our company analysis, valuation work, and reading of clinical data at a professional standard.
Mentorship
Members will share career guidance with our student analysts across biotech, healthcare finance, and medicine.
Industry Perspective
The board will connect our research and programs with what is happening inside companies, funds, and health systems.
Get in Touch
Interested in Advising BioAsset?
Reach out directly and we’ll find the right way to work together.
Site Index
BioAsset in Plain Text
Everything on this site in one readable list: who we are, our research, our team, our conversations, and our programs.
About BioAsset
BioAsset is a student-run research platform at the intersection of life sciences and capital markets. A global team of student analysts publishes deep dives, company analyses, educational primers, and open financial models, and interviews leaders across biotech, healthcare finance, and the life sciences.
The most important developments in healthcare are driven by capital, science, and policy working together. BioAsset exists to make that intersection legible to the next generation of analysts, investors, and physicians.
Research (47 posts, each also as an article)
- The Quiet (and Growing) Giant of US Healthcare: Cardinal HealthAlay Galvankar · Company Analysis · 7 slides
- Long Aktis Oncology (AKTS): Investment PitchDmitry Vysotskiy · Investment Pitch · 18 pages · PDF
- The FDA has approved Takeda’s oveporexton, the first orexin agonist for narcolepsyJoy Wu · FDA Approval · 5 slides
- Designer-ish Babies: Will it be the Future?Jingqiu Tian · Industry Trends · 7 slides
- FDA Approves Rasonque: The First RAS-Targeted Drug for Pancreatic CancerNeev Mohindroo · FDA Approval · 4 slides
- The Parkinson’s Bet That Couldn’t Hold $15: Aspen Neuroscience’s IPOJudy Dalati · Company Analysis · 5 slides
- A $1.3B Bet: Merck KGaA Buys Silence TherapeuticsViren Jain · Company Analysis · 5 slides
- From the Space Race to the Biotech Race: China Guards Its LeadJudy Dalati · Industry Trends · 5 slides
- The Shovel Sellers of AI Biology: Twist BioscienceNeev Mohindroo · Company Analysis · 5 slides
- The Price to Pay to End an mRNA Vaccine Fight: Up to $2.25B to be Paid by ModernaJingqiu Tian · Company Analysis · 5 slides
- $6.7B: Merck’s Leukemia Drug Acquisition That Could Shake Up The MarketAlay Galvankar · Company Analysis · 5 slides
- UK Biobank: Turning Biological Data into Drug DiscoveryBrendan Seo · Deep Dive · 5 slides
- Saliva, Stress, and Startups: The Rise of Cortisol TestingJoy Wu · Industry Trends · 5 slides
- Tectonic Therapeutic (TECX): Long Thesis Memo & Financial ModelBenjamin Shar · Memo + Model · 12 pages · PDF + XLSX
- CRISPR’s Fatal Test: Intellia’s In-Vivo Reality CheckDmitry Vysotskiy · 4 slides
- $11 Insulin: California Rewrites the Prescription on Big PharmaDmitry Vysotskiy · 4 slides
- Roche Pill Delays Tumor Progression in Closely Watched Breast Cancer StudyDmitry Vysotskiy · 5 slides
- Blackstone x TPG Make Hologic Private ($18.3B)Dmitry Vysotskiy · 4 slides
- Inside China’s Transformative Global Biotech BoomDmitry Vysotskiy · 4 slides
- The $30 Million Bet: How Valthos and AI Are Rewriting BiodefenseDmitry Vysotskiy · 4 slides
- Eli Lilly vs Novo Nordisk: Who Will Win the GLP-1 Race?Dmitry Vysotskiy · 5 slides
- From Chips to Clinics: Nvidia Expands Its Healthcare AmbitionsDmitry Vysotskiy · 5 slides
- Breaking Bones: Inside J&J’s Orthopedics SpinoffDmitry Vysotskiy · 5 slides
- From One Drop to Fifty Diagnoses: How Blood May Be the Next Frontier of Cancer DetectionDmitry Vysotskiy · 5 slides
- Biotech X Beauty: The Future of SkincareDmitry Vysotskiy · 5 slides
- America’s GLP-1 Paradox: Obesity Falls, Diabetes RisesDmitry Vysotskiy · 5 slides
- AI’s Early Footprint: Optimized Peptides for Efficient Protein ProductionDmitry Vysotskiy · 5 slides
- BioAsset VC Dive: Predict Before You Test — Axiom and AI ToxicologyDmitry Vysotskiy · 5 slides
- AI x Drug Discovery: From Computation To CureDmitry Vysotskiy · 4 slides
- BioAsset Autopsies: The Intarcia StoryDmitry Vysotskiy · 5 slides
- BioAsset Weekly: The Pricing Wars, Regulation and M&ADmitry Vysotskiy · 5 slides
- Update: Revolution MedicinesBrendan Seo · 1 slide
- Parasites as Biotech Assets: From Disease to Drug DiscoveryBrendan Seo · 5 slides
- Replimune’s Stock Crash After FDA RejectionBrendan Seo · 5 slides
- Atavistik Bio: $160M to Drug the Undruggable and Cure a Rare Blood DisorderJingqiu Tian · 5 slides
- Alternative Prostate Cancer Treatment: Targeting Thyroid Hormone ReceptorsJingqiu Tian · 5 slides
- Treating the Impossible: Novel Treatments Potentially Curing Type 1 DiabetesJingqiu Tian · 5 slides
- Update: BMS x AnthropicAlay Galvankar · 1 slide
- Growth: Radioisotope Supply BoostAlay Galvankar · 1 slide
- Update: Replimune Stock SurgesAlay Galvankar · 1 slide
- Novo X Hims: From Lawsuit to Partnership — What It Means for GLP-1Alay Galvankar · 5 slides
- Fast-Tracked: How Hernexeos Won FDA Approval in 44 DaysAlay Galvankar · 5 slides
- BioAsset VC Dive: Xaira Therapeutics — Can AI Crack the Drug Discovery Code?Alay Galvankar · 5 slides
- Regeneron x CytomXNeev Mohindroo · 5 slides
- Lilly NeuroscienceNeev Mohindroo · 5 slides
- All Eyes On Cancer TherapySharath Venkatesan · 1 slide
- The Cost of Uncertainty: uniQure’s Battle with the FDASharath Venkatesan · 6 slides
Team
- Dmitry VysotskiyFounder & President · NYU Stern, Finance & Quantitative Economics
Founder and President of BioAsset. Finance and Quantitative Economics student at NYU Stern with a minor in Computer Science. Prior research experience at NYU Langone and Weill Cornell, with clinical exposure in surgery and gastroenterology. Leads strategy, editorial direction, and partnerships, focused on making the intersection of life sciences and capital markets accessible to a broader audience.
- Alay GalvankarLead Analyst & Vice President · NYU, Global Public Health & Biology
Lead Analyst and Vice President at BioAsset. Studies Global Public Health and Biology at NYU, with minors in Chemistry and Business Studies. Leads research direction across biopharma and pharma strategy, focused on bridging scientific innovation with capital markets and broader public understanding.
- Joy WuLead Analyst · NYU, Biology & Business Studies
Lead Analyst at BioAsset. Biology and Business Studies student at NYU with prior clinical exposure at Shanghai Shuguang Hospital. Leads research coverage and weekly biotech news analysis, with a focus on how immunology and physiology shape drug development.
- Brendan SeoResearch Analyst · NYU, Economics
Research Analyst at BioAsset. Economics student at NYU focused on the intersection of finance, investing, and biotech. Contributes company analyses, sector overviews, and editorial commentary on developments shaping the life sciences industry.
- Jingqiu TianResearch Analyst · University of Cambridge, Biological Natural Sciences
Research Analyst at BioAsset. Biological Natural Sciences student at the University of Cambridge. Brings a scientific lens to biotech market analysis, focused on translating clinical and pipeline developments into accessible, investor-relevant insights.
- Yaz ArulthasanOutreach · NYU, Biology
Outreach team member at BioAsset. Biology student at NYU. Focused on building partnerships, expanding organizational reach, and connecting BioAsset’s content with the broader biotech and healthcare finance community.
- Benjamin SharResearch Analyst · NYU Stern, Finance
Research Analyst at BioAsset. Finance student at NYU Stern. Contributes company analyses, sector deep dives, and financial modeling across the biopharma and healthcare landscape, with a focus on drug development and market dynamics.
- Sharath VenkatesanResearch Analyst · NYU, Biochemistry
Research Analyst at BioAsset. Biochemistry student at NYU focused on the intersection of medicine and the financial decisions that shape patient care. Contributes research coverage and editorial commentary across the biopharma and healthcare landscape.
- Neev MohindrooResearch Analyst · Rutgers University, Finance
Research Analyst at BioAsset. Finance major and biology minor at Rutgers University with a STEM-focused high school background and experience sourcing biotech startups through Rutgers Venture Capital Club. Drawn to the intersection of healthcare innovation and markets, with a focus on making biotech and healthcare finance ideas quicker to understand for readers who are curious about both fields.
- Viren JainResearch Analyst · NYU CAS, Economics
Research Analyst at BioAsset. Economics & Business student at NYU interested in the intersection of pharmaceuticals, finance, and business strategy. Brings prior experience in equity research and competitive analysis, and is focused on developing a deeper understanding of the business and investment decisions shaping the biopharma industry.
- Judy DalatiResearch Analyst · NYU CAS, Global Public Health & Biology
Research Analyst at BioAsset. Global Public Health and Biology student at NYU with a minor in Business Studies. Focused on how biology, technology, and finance can work together to strengthen healthcare systems and make care more accessible and efficient, with particular interest in how biological innovations become real-world solutions.
- Olga SpasicResearch Analyst · NYU, Biology
Research Analyst at BioAsset. Biology and Business student with hands-on experience in next-generation sequencing, genomic data analysis, and a broad range of molecular biology techniques at PathoQuest SAS. Pursuing a minor in Business Studies to bridge laboratory research with patient outcomes and healthcare contexts.
Expert Interviews
- Dr. Omar B. LateefPresident & CEO, RUSH University System for Health
Upcoming conversation.
- Sofia AxelrodCo-Founder & CEO, Circadian OS
Circadian medicine, optimizing cancer treatment timing, and translating circadian rhythm research into clinical impact
- Jay SchiffAddinex Technologies
Medtech innovation, bringing devices from concept to commercialization
- Andy BoltDeloitte Life Sciences
How consulting intersects with biopharma strategy, and navigating a non-linear career path
- Dr. Ron MarksBiostatistician
The role of statistics in drug development, clinical trial design, and interpreting endpoint data
- Annika LundströmCo-Founder & CEO, ReMinded
Building a cortisol biotech startup
- Dr. Ayoub GliaScientist & Engineer, AMMLab, NYU Abu Dhabi
Microfluidic innovation, paper-based diagnostics, 3D tumor models, and accessible biomedical engineering for global health
- Dr. Paul GlimcherProfessor of Neuroscience & Economics, NYU
Neuroeconomics, decision-making under uncertainty, and the convergence of neuroscience and finance
- Dr. Michele PaganoChair, Department of Biochemistry & Molecular Pharmacology, NYU
Cell cycle control, ubiquitin-proteasome system, and translating fundamental research into oncology drug discovery
- Dr. Hao SuDirector, Biomechatronics & Intelligent Robotics Lab, NYU Tandon
AI-powered wearable robotics, exoskeletons, and minimally invasive surgical robots transforming rehabilitation and medical procedures
Video Interviews
- Why and how ReMinded was started, with Co-Founder & CEO Annika LundströmYaz Arulthasan · Instagram
- ReMinded Co-Founder & CEO Annika Lundström on prioritizing what actually mattersYaz Arulthasan · Instagram
- Co-Founder & CEO Annika Lundström on the future trajectory of ReMindedYaz Arulthasan · Instagram
Clients and Partnerships
- ReMindedCurrent Client · Official Partner · Since Fall 2026
A New York medtech building clinical-grade saliva testing, starting with cortisol. Our work together: Strategic marketing and campaigns, with a consulting project or case study to follow.
Advisory Board
Our founding advisory board will be announced soon.
Fall 2026 Curriculum
- Week 1: Introduction to BioAsset and Life Sciences + Careers + Resume Workshop
- Week 2: How Money Flows Through the Healthcare Ecosystem
- Week 3: Biotech & Pharma Fundamentals
- Week 4: Clinical Trials & Clinical Data
- Week 5: FDA, Regulation & Catalysts
- Week 6: Commercialization & Market Access
- Week 7: Healthcare History, Ethics & Current Problems
- Week 8: Biotech Revenue Forecasting
- Week 9: How to Analyze a Public Healthcare Company
- Week 10: Biotech Valuation & Investment Thinking
- Week 11: M&A, Licensing & Strategic Finance + Fun Activities
Contact
Email bioasset@bioasset.info. BioAsset is on LinkedIn, Instagram, TikTok, and YouTube.







